Filing Details
- Accession Number:
- 0001179110-15-004022
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-03-03 17:04:31
- Reporting Period:
- 2015-03-02
- Filing Date:
- 2015-03-03
- Accepted Time:
- 2015-03-03 17:04:31
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1436304 | Kythera Biopharmaceuticals Inc | KYTH | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1559531 | E Nathaniel David | C/O Kythera Biopharmaceuticals, Inc. 30930 Russell Ranch Road, 3Rd Floor Westlake Village CA 91362 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2015-03-02 | 1,175 | $39.95 | 479,420 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-02 | 400 | $41.67 | 479,020 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-02 | 300 | $42.80 | 478,720 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan which expires April 30, 2015.
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $39.38 to $40.26, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $41.16 to $41.95, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $42.50 to $43.20, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.